Virtual reality workouts tested for rare lung condition
NCT ID NCT07558460
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether exercise delivered through immersive virtual reality can improve physical performance, muscle strength, fatigue, and quality of life in 32 adults with idiopathic pulmonary arterial hypertension. Participants will do virtual reality exercises and be measured on walking distance, strength, and breathlessness. The goal is to see if this fun, engaging approach can make exercise more effective and accessible for people with this serious lung condition.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 32 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2026
- Expected to finish
-
Jan 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Diagnosis of Idiopathic Pulmonary Arterial Hypertension, * Stable pharmacological treatment for the past 3 months, * Hemodynamic and clinical stability for at least the past three months, * Age of 18-65, * Voluntary participation in the study and signing the informed consent form, * Being classified in the World Health Organization-Functional Classification I, II or III. Exclusion Criteria: * The presence of an orthopedic or neurological problem that will affect functional tests and muscle strength measurement, * Acute decompensated heart failure, * Unstable angina pectoris, * Uncontrolled hypertension, * The presence of problems that hinder communication, * Dizziness, vertigo, * Severe visual impairment,
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Idiopathic pulmonary arterial hypertension are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Istanbul University-Cerrahpaşa/ Cardiology Institute
Istanbul, Fatih, 34180, Turkey (Türkiye)
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can bosentan reverse lung artery thickening? small study investigates
- Fat in the heart: new clues for PAH?
- Can a traditional chinese herb pill help Lung-Heart patients breathe easier?
- New study seeks clues to why some get PAH and others Don't
- New PET tracer could spot deadly lung disease years earlier
- Researchers dive into why scleroderma and lung hypertension weaken the heart